Farrah Kheradmand, MD, explains the effects of vaping duration on lung function.
When mice were exposed to 3 months of electronic cigarettes, and then exposed them to influenza, these mice succumbed to influenza much faster, said Farrah Kheradmand, MD, a professor of medicine-pulmonary at Baylor College of Medicine and a staff physician at the Houston Veterans Affairs (VA) medical center. Kheradmand's research was presented at this year's American Thoracic Society (ATS) 2021 virtual conference.
Transcript:
Based on your research, would you expect to see differential outcomes based on time of use, or repeated use of vapes?
Yes, and that's exactly what we found. We found that as early as a month, if you take these alveolar macrophages and put them in culture, and then try to simulate a scenario where they actually need to activate some markers, some genes, and some proteins, in order to combat a virus, they're not doing that. They're not doing a normal function as early as a month. Now, when we then took these mice and exposed them to 3 months of electronic cigarette, and then exposed them, in real life, to influenza these mice succumbed to influenza much faster and lost a lot more weight, and they were much, much sicker, again, independent of nicotine, than mice that were exposed to air.
What are the next steps for your research?
Yes, so lots of interesting questions fall out of that. One of the missions of my lab is to try to crack this story further open so we could see that if we get patients with electronic induced vaping and electronic-associated lung injury, how can we help them? How can we go back and now reverse the pathology? We have some ideas; we have some molecules in mind. We know that the macrophages display very different cell surface markers, and we're trying to understand what makes the sulfur surface markers different. We’re basically pursuing lots of different mediators that correlate with the changes and we're going to functionally change them or re-expose them to the some of these missing factors to see if that can reverse the process.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More